Get started
666

SICHUAN KELUN-BIOTECH BIOPHARMACEUT

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Forecast Seasonals

6990 chart


Full chart

6990 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪39.44 B‬ HKD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.1 HKD
Net income (FY)
‪−577.04 M‬ HKD
Revenue (FY)
‪1.70 B‬ HKD
Shares float
‪22.38 M‬
Beta (1Y)
0.88

Employees


Employees (FY)
‪1.42 K‬
Revenue / Employee (1Y)
‪154.02 K‬ HKD
Net income / Employee (1Y)
‪−52.21 K‬ HKD

About SICHUAN KELUN-BIOTECH BIOPHARMACEUT


Sector
Health Technology
CEO
Jun You Ge
Headquarters
Chengdu
Founded
2016
ISIN
CNE1000062J1
FIGI
BBG01H7W3K69
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. engages in the research and development, manufacture, and commercialization of novel drugs. It offers proprietary technology platforms focusing on the treatment of breast cancer, non-small cell lung cancer, gastrointestinal cancers, and colorectal cancer, as well as non-oncology diseases. The company was founded by Ge Xin Liu on November 22, 2016 and is headquartered in Chengdu, China.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

6990 news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 6990 is 183.5 HKD — it has increased by 3.84% in the past 24 hours. Watch SICHUAN KELUN-BIOTECH BIOPHARMACEUT stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange SICHUAN KELUN-BIOTECH BIOPHARMACEUT stocks are traded under the ticker 6990.
6990 stock has fallen by −5.45% compared to the previous week, the month change is a −8.01% fall, over the last year SICHUAN KELUN-BIOTECH BIOPHARMACEUT has showed a 113.37% increase.
We've gathered analysts' opinions on SICHUAN KELUN-BIOTECH BIOPHARMACEUT future price: according to them, 6990 price has a max estimate of 244.31 HKD and a min estimate of 196.26 HKD. Watch 6990 chart and read a more detailed SICHUAN KELUN-BIOTECH BIOPHARMACEUT stock forecast: see what analysts think of SICHUAN KELUN-BIOTECH BIOPHARMACEUT and suggest that you do with its stocks.
6990 reached its all-time high on Oct 4, 2024 with the price of 223.8 HKD, and its all-time low was 60.6 HKD and was reached on Jul 11, 2023. View more price dynamics on 6990 chart.
See other stocks reaching their highest and lowest prices.
6990 stock is 4.89% volatile and has beta coefficient of 0.88. Track SICHUAN KELUN-BIOTECH BIOPHARMACEUT stock price on the chart and check out the list of the most volatile stocks — is SICHUAN KELUN-BIOTECH BIOPHARMACEUT there?
Today SICHUAN KELUN-BIOTECH BIOPHARMACEUT has the market capitalization of ‪40.96 B‬, it has decreased by −8.89% over the last week.
Yes, you can track SICHUAN KELUN-BIOTECH BIOPHARMACEUT financials in yearly and quarterly reports right on TradingView.
SICHUAN KELUN-BIOTECH BIOPHARMACEUT is going to release the next earnings report on Mar 25, 2025. Keep track of upcoming events with our Earnings Calendar.
6990 earnings for the last half-year are 1.51 HKD per share, whereas the estimation was −1.16 HKD, resulting in a 230.59% surprise. The estimated earnings for the next half-year are −3.07 HKD per share. See more details about SICHUAN KELUN-BIOTECH BIOPHARMACEUT earnings.
SICHUAN KELUN-BIOTECH BIOPHARMACEUT revenue for the last half-year amounts to ‪1.49 B‬ HKD, despite the estimated figure of ‪919.26 M‬ HKD. In the next half-year revenue is expected to reach ‪628.85 M‬ HKD.
6990 net income for the last half-year is ‪336.17 M‬ HKD, while the previous report showed ‪−586.63 M‬ HKD of net income which accounts for 157.31% change. Track more SICHUAN KELUN-BIOTECH BIOPHARMACEUT financial stats to get the full picture.
No, 6990 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has ‪1.42 K‬ employees. See our rating of the largest employees — is SICHUAN KELUN-BIOTECH BIOPHARMACEUT on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SICHUAN KELUN-BIOTECH BIOPHARMACEUT EBITDA is ‪−184.59 M‬ HKD, and current EBITDA margin is −26.18%. See more stats in SICHUAN KELUN-BIOTECH BIOPHARMACEUT financial statements.
Like other stocks, 6990 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SICHUAN KELUN-BIOTECH BIOPHARMACEUT stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SICHUAN KELUN-BIOTECH BIOPHARMACEUT technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SICHUAN KELUN-BIOTECH BIOPHARMACEUT stock shows the strong buy signal. See more of SICHUAN KELUN-BIOTECH BIOPHARMACEUT technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.